Lakefront Biotherapeutics NV (LKFT)
LKFTNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$33.41
-0.1100 (-0.33%) today
At the close, Nov 10, 4:00 PM ET. After hours $33.41 –
- Market cap
- $2.20bn
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- $32.80 to $33.48
- 52-week range
- $25.68 to $36.24
- Average volume
- 284.7k
- Previous close
- $33.52
Analysts
2 coveringUnderperform1 buy, 1 hold, 0 sell
Targets a year out average $35.50, +6.3% from here
Earnings
next estimate $-0.1900Next report
Mar 2026
+119.7%
estimate reported, and the surprise
Financials
| Quarter | Dec 2012 |
|---|---|
| Revenue | $121.59m |
| Gross profit | $114.23m |
| Operating income | -$12.56m |
| Net income | -$7.54m |
News
8 latest- Should You Buy Lakefront Biotherapeutics - Sponsored ADR (LKFT) After Golden Cross?Zacks · 4 days ago
- Galapagos NV Announces Gamgertamig Preliminary Phase 1b Data and Poster Presentation at 2026 ASH MeetingFintel · 6 days ago
- Lakefront Biotherapeutics - Sponsored ADR (LKFT) Upgraded to Buy: What Does It Mean for the Stock?Zacks · Oct 21, 2026
- Lakefront Biotherapeutics Transfers CAR-T Assets To Armed Cell Therapeutics RTTNews · Oct 15, 2026
- Lakefront Biotherapeutics Targets 2027 Registrational Trials for GamgertamigMarketBeat · Sep 21, 2026
- Lakefront's Gamgertamig Receives Orphan Drug Status For Pemphigus RTTNews · Aug 24, 2026
- Galapagos Enters Framework Agreement With Gilead In Connection With Ouro Deal RTTNews · Mar 31, 2026
- Gilead Strengthens Inflammation Portfolio With Ouro Medicines DealZacks · Mar 24, 2026
The company
Lakefront Biotherapeutics is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. The Company has established a clinical-stage portfolio in immunology and inflammation, anchored by gamgertamig, a potential first-in-class and best-in-class BCMAxCD3 T-cell engager for autoimmune diseases. Backed by deep deal-making expertise, operational flexibility, and a strong capital position, Lakefront identifies, acquires, and advances high-quality assets with clear potential to deliver meaningful patient impact and long-term shareholder value. For more information, visit https://www.lakefrontbio.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- Europe
- Website
- glpg.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.